

# **Institutional Review Board statement**

**Title:**


Telbivudine versus tenofovir in HBeAg-negative chronic hepatitis B patients: OPTIMA roadmap study

**Authors:**

Zahari Krastev, Diana Petrova, Iskren Kotzev, Celen Mustafa Kemal, Kamal Hamed, Richa Chandra

The study received approval from the Ethik-Kommission der Medizinischen Universität Wien und des Allgemeinen Krankenhauses der Stadt in Austria; Ethics Committee for Multicentre Trials in Bulgaria; RF MoHSD, Department of State Regulation of Circulation of Medicines, Ethics Council in Russia; National Ethics Committee for Clinical Trials in Greece; Comitato Etico Azienda Ospedaliera Universitaria Policlinico P. Giaccone in Italy; Institut Municipal D'Investigació mèdica in Spain; Ethik-Kommission der Albert-Ludwigs-Universität Freiburg in Germany; Ege University Medical Faculty Clinical Researches Ethical Committee in Turkey.

**Corresponding author:**



Dr Richa Chandra,

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA

14 March 2016,